Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024



STOCKHOLM, Feb. 8, 2024 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2023.

Fourth Quarter 2023

Total revenue increased 14 per cent, 15 per cent at constant exchange rates, (CER), to SEK 6,844 M (5,991)           
Haematology revenue increased 21 per cent at CER to SEK 3,640 M (3,025), driven by sales of Vonjo® of SEK 322 M, strong sales of SEK 1,323 M for Elocta®, growth for Doptelet® excluding China of 59 per cent at CER and sales of Aspaveli®/Empaveli® of SEK 186 M           
Immunology revenue increased 10 per cent at CER to SEK 2,905 M (2,643), driven by Gamifant® growth of 107 per cent at CER and royalties on Beyfortus™ (nirsevimab) of SEK 890 M           
The adjusted EBITA margin was 38 per cent (41), excluding items affecting comparability (IAC). EBITA was SEK 2,502 M (2,455), corresponding to a margin of 37 per cent (41). EBIT was SEK 1,610 M (1,916)           
Earnings per share (EPS) before dilution was SEK 3.02 (4.47). EPS adjusted before dilution was SEK 3.21 (4.47). Cash …

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *